Ruidong Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ruidong Li has a total of 142 co-authors. Here are the top co-authors by number of shared publications:
Jianguo Zhu
19 shared publicationsWei-De Zhong
18 shared publicationsZhenyu Jia
15 shared publications- Zhenyu Jia
University of California, Riverside
9 shared publications Han Qu
Department of Botany and Plant Sciences, University of California, Riverside, CA, USA
5 shared publicationsJohn M Chater
Department of Botany and Plant Sciences, University of California, Riverside, CA, USA
4 shared publications
Latest Publications
- Open Access
- 24 September 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (D1) , D1590-D1607
Rare Cancer Explorer 1.0 (RaCE 1.0): a dedicated database and analytical platform focused on rare cancers
Rare cancers face major research challenges due to limited sample sizes and data scarcity. Existing pan-cancer databases mainly focus on common cancer types, while rare cancers often lack sufficient attention and systematic data collection. In addition, their high heterogeneity and the scarcity of studies on genomic features, immune environments, and drug responses lead to significant gaps in current databases and analytical tools. To address these limitations, we developed the Rare Cancer Explorer (RaCE), a dedicated database for integrated curation, analysis, and visualization of rare cancers. RaCE consolidates 5451 samples spanning 13 rare solid tumor types from 69 independent datasets, offering researchers a one-stop data analysis toolkit. The database provides one integrated dataset meta-analysis module and eight dedicated rare cancer functional analysis modules, including transcriptomics, immune infiltration, and immunotherapy response prediction, with a specialized focus on modeling gene effects and drug sensitivity in rare cancer cell lines. RaCE distinguishes itself through robust interactive functionalities, enabling users to seamlessly explore multi-layered insights from gene functions to therapeutic targets, thereby accelerating precision medicine and translational research for rare cancers. Compared to existing databases, RaCE demonstrates unique advantages in supporting rare cancer research through comprehensive data integration. The database is freely accessible at https://biospace.shinyapps.io/race/ or https://hiplot.com.cn/race/.
- 24 September 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 54 (D1) , D1590-D1607
Open AccessRare Cancer Explorer 1.0 (RaCE 1.0): a dedicated database and analytical platform focused on rare cancers
Rare cancers face major research challenges due to limited sample sizes and data scarcity. Existing pan-cancer databases mainly focus on common cancer types, while rare cancers often lack sufficient attention and systematic data collection. In addition, their high heterogeneity and the scarcity of studies on genomic features, immune environments, and drug responses lead to significant gaps in current databases and analytical tools. To address these limitations, we developed the Rare Cancer Explorer (RaCE), a dedicated database for integrated curation, analysis, and visualization of rare cancers. RaCE consolidates 5451 samples spanning 13 rare solid tumor types from 69 independent datasets, offering researchers a one-stop data analysis toolkit. The database provides one integrated dataset meta-analysis module and eight dedicated rare cancer functional analysis modules, including transcriptomics, immune infiltration, and immunotherapy response prediction, with a specialized focus on modeling gene effects and drug sensitivity in rare cancer cell lines. RaCE distinguishes itself through robust interactive functionalities, enabling users to seamlessly explore multi-layered insights from gene functions to therapeutic targets, thereby accelerating precision medicine and translational research for rare cancers. Compared to existing databases, RaCE demonstrates unique advantages in supporting rare cancer research through comprehensive data integration. The database is freely accessible at https://biospace.shinyapps.io/race/ or https://hiplot.com.cn/race/.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
Overtreatment remains a pervasive problem in prostate cancer management due to the highly variable and often indolent course of disease. Molecular signatures derived from gene expression profiling have played critical roles in guiding prostate cancer treatment decisions. Many gene expression signatures have been developed to improve the risk stratification of prostate cancer and some of them have already been applied to clinical practice. However, no comprehensive evaluation has been performed to compare the performance of these signatures. In this study, we conducted a systematic and unbiased evaluation of 15 machine learning (ML) algorithms and 30 published prostate cancer gene expression–based prognostic signatures leveraging 10 transcriptomics datasets with 1,558 primary patients with prostate cancer from public data repositories. This analysis revealed that survival analysis models outperformed binary classification models for risk assessment, and the performance of the survival analysis methods—Cox model regularized with ridge penalty (Cox-Ridge) and partial least squares (PLS) regression for Cox model (Cox-PLS)—were generally more robust than the other methods. Based on the Cox-Ridge algorithm, several top prognostic signatures displayed comparable or even better performance than commercial panels. These findings will facilitate the identification of existing prognostic signatures that are promising for further validation in prospective studies and promote the development of robust prognostic models to guide clinical decision-making. Moreover, this study provides a valuable data resource from large primary prostate cancer cohorts, which can be used to develop, validate, and evaluate novel statistical methodologies and molecular signatures to improve prostate cancer management.Significance:This systematic evaluation of 15 machine learning algorithms and 30 published gene expression signatures for the prognosis of prostate cancer will assist clinical decision-making.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
Overtreatment remains a pervasive problem in prostate cancer management due to the highly variable and often indolent course of disease. Molecular signatures derived from gene expression profiling have played critical roles in guiding prostate cancer treatment decisions. Many gene expression signatures have been developed to improve the risk stratification of prostate cancer and some of them have already been applied to clinical practice. However, no comprehensive evaluation has been performed to compare the performance of these signatures. In this study, we conducted a systematic and unbiased evaluation of 15 machine learning (ML) algorithms and 30 published prostate cancer gene expression–based prognostic signatures leveraging 10 transcriptomics datasets with 1,558 primary patients with prostate cancer from public data repositories. This analysis revealed that survival analysis models outperformed binary classification models for risk assessment, and the performance of the survival analysis methods—Cox model regularized with ridge penalty (Cox-Ridge) and partial least squares (PLS) regression for Cox model (Cox-PLS)—were generally more robust than the other methods. Based on the Cox-Ridge algorithm, several top prognostic signatures displayed comparable or even better performance than commercial panels. These findings will facilitate the identification of existing prognostic signatures that are promising for further validation in prospective studies and promote the development of robust prognostic models to guide clinical decision-making. Moreover, this study provides a valuable data resource from large primary prostate cancer cohorts, which can be used to develop, validate, and evaluate novel statistical methodologies and molecular signatures to improve prostate cancer management.Significance:This systematic evaluation of 15 machine learning algorithms and 30 published gene expression signatures for the prognosis of prostate cancer will assist clinical decision-making.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
Supplementary Table from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
Supplementary Table from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
Supplementary Table from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
Supplementary Table from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
Supplementary Table from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
Supplementary Table from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
Supplementary Table from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
Supplementary Table from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
Supplementary Figure from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
Supplementary Figure from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
Supplementary Table from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
Supplementary Table from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
Supplementary Table from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
Supplementary Table from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
Supplementary Figure from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts
Supplementary Figure from Comprehensive Evaluation of Machine Learning Models and Gene Expression Signatures for Prostate Cancer Prognosis Using Large Population Cohorts